FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average	hurdon								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID AFFROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

					T																
1. Name and Address of Reporting Person*					2. Is	2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Peraza Lisa														(Director 10% Owner				ner		
-					_ HRTX]									(give title		Other (s	pecify				
(Last)	(F	irst)	(Middle)											-	below,		,.	below)			
4242 CAMPUS POINT COURT						3. Date of Earliest Transaction (Month/Day/Year) 10/13/2022										VP, C	Intel Acc	ounti	ing Office		
SUITE 200					10,																
SOTTE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable					
(Street)															- 1	Line) X Form filed by One Reporting Person					
SAN DII	EGO C.	A	92121													l ' ' '					
-					-											Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																		
		Tab	le I - No	n-Deriv	vative	Se	curiti	ies Ac	qu	ıired,	Dis	posed o	of, or	Ben	eficial	ly Owne	d				
1. Title of	Security (Ins	tr. 3)		2. Trans	action					3. 4. Securities Acquired (A) of								7. Nature			
				Date (Month/Day/\			Execution Date, if any			Transaction Code (Instr.					. 3, 4 and	Securiti Benefic			rm: Direct) or Indirect	of Indirect Beneficial	
				l`	•		(Month/Day/Year)					· -'					Following (I)			Ownership Instr. 4)	
										Code	V	Amount	(4	A) or D)	Price	Transac (Instr. 3	ction(s)		ľ		
Common	Stock			10/13	3/2022	/2022				М		553		A	(1)	19	,518		D		
0	C ₁ 1			10/10	2/2022				\dashv			1.022		(1)	_	<u> </u>		D			
Common Stock				10/13	3/2022	2022				M		1,932	2 A		(1)	21,450			D		
Common Stock 10/13/2					3/2022	2022			F		861 D ⁽²⁾		\$3.7	20,589			D				
		T	able II -													Owned					
				(e.g., p	outs,	call	s, wa	rrants	s, o	ption	s, c	onverti	ble s	ecur	ities)						
1. Title of	2.	3. Transaction	3A. Deem		4.	-41		umber		Date Exe			7. Titl			8. Price of	9. Number		10.	11. Nature	
Derivative Conversion Date Execution Date Security or Exercise (Month/Day/Year) if any					nsaction of le (Instr. Derivative		Derivative (M		Expiration Date (Month/Day/Year)			Amount of Securities			Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial		
(Instr. 3)	Price of Derivative		(Month/Da	(Month/Day/Year)				Securities Acquired					Underlying Derivative Secu		acurity	(Instr. 5)	Beneficially Owned	ly	Direct (D) or Indirect	Ownership (Instr. 4)	
	Security						(A) or					(Instr. 3 ar					Following Reported Transaction(s)		(I) (Instr. 4)	(111301. 4)	
							Disp of (I	isposed (D)								on(s)		.l			
							(Ins	r. 3, 4								(Instr. 4)					
				ŀ			and 5)		H												
														0	Amount						
									Dat			xpiration			Number of						
					Code	٧	(A)	(D)	Exc	ercisabl	e D	ate	Title	s	Shares						
Restricted Stock Units	(1)	10/13/2022			M			553		(3)		(3)	Comr		553	\$0.00	4,416		D		
Restricted Stock Units	(1)	10/13/2022		Ì	M			1,932		(4)	T	(4)	Comr		1,932	\$0.00	15,694		D		

Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
- 3. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
- 4. The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Remarks:

/s/ Lisa Peraza ** Signature of Reporting Person 10/17/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.